You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nucleos(t)ide therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Hepatitis B Trial in Hong Kong, Auckland (VRON-0200-AdC6, VRON-0200-AdC7)

Recruiting
  • Chronic Hepatitis B
  • VRON-0200-AdC6
  • VRON-0200-AdC7
  • Hong Kong, Hong Kong
  • +1 more
Oct 6, 2023

Hepatitis B Trial in Worldwide (GSK3228836, Nucleos(t)ide therapy)

Recruiting
  • Hepatitis B
  • Boston, Massachusetts
  • +3 more
Aug 24, 2022

Chronic Hepatitis b Trial in Taiwan (Nuc Discontinuation, Entecavir or Tenofovir)

Active, not recruiting
  • Chronic Hepatitis b
  • Nuc Discontinuation
  • Entecavir or Tenofovir
  • Chiayi City, Taiwan
  • +5 more
Mar 30, 2023

Chronic Hepatitis B Trial in Beijing (TCR-T)

Active, not recruiting
  • Chronic Hepatitis B
  • TCR-T
  • Beijing, China
    The Fifth Medical Center of PLA General Hospital
Jun 13, 2023

Chronic Hepatitis B Virus Infection Trial in Kaohsiung, Taichung, Taipei (Ropeginterferon alfa-2b, Entecavir)

Recruiting
  • Chronic Hepatitis B Virus Infection
  • Kaohsiung, Taiwan
  • +4 more
Aug 12, 2022

After Long-Term Antiviral Treatment for Chronic Hepatitis B

Completed
  • Chronic Hepatitis B e Antigen Positive
  • Chronic Hepatitis B e Antigen Negative
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 26, 2023

    Hepatitis B, Chronic Trial in Belgium, Germany, United Kingdom (JNJ-64300535, Placebo, Nucleos(t)ide Analogs (NA))

    Completed
    • Hepatitis B, Chronic
    • JNJ-64300535
    • +2 more
    • Antwerp, Belgium
    • +13 more
    Apr 13, 2021

    Chronic Hepatitis B Trial in Guangzhou (NrtIs, HH-003, HH-003+NrtIs)

    Active, not recruiting
    • Chronic Hepatitis B
    • Guangzhou, Guangdong, China
      Nanfang Hospital, Southern Medical University
    Apr 20, 2023

    Chronic Hepatitis B After Nucleos(t)Ide Analogue Therapy

    Completed
    • Virological Breakthrough
    • Prognosis
    • Observation for clinical and virological changes
    • Changhua, Taiwan
    • +3 more
    Mar 14, 2021

    Chronic Hepatitis B, High-Risk Cancer Trial in China (Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue, Nucleos(t)ide

    Active, not recruiting
    • Chronic Hepatitis B
    • High-Risk Cancer
    • Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue
    • Nucleos(t)ide analogue
    • Chengdu, China
    • +8 more
    Jan 4, 2023

    Chronic Hepatitis B Trial (Bepirovirsen, Placebo)

    Recruiting
    • Chronic Hepatitis B
    • Herston, Queensland, Australia
    • +7 more
    Jan 23, 2023

    Hepatitis B, Chronic Trial in Worldwide (GSK3228836, GSK3528869A, Control)

    Recruiting
    • Hepatitis B, Chronic
    • Edegem, Belgium
    • +47 more
    Jan 24, 2023

    Chronic Hepatitis B Trial in Worldwide (Bepirovirsen, Placebo)

    Recruiting
    • Chronic Hepatitis B
    • Victoria, British Columbia, Canada
    • +10 more
    Jan 23, 2023

    Cirrhosis, Liver, Portal Hypertension Trial in Beijing, Shanghai (Carvedilol)

    Recruiting
    • Cirrhosis, Liver
    • Portal Hypertension
    • Beijing, Beijing, China
    • +5 more
    Jan 26, 2022

    Hepatitis B, Chronic Trial in China (Tenofovir Alafenamide 25 MG)

    Recruiting
    • Hepatitis B, Chronic
    • Tenofovir Alafenamide 25 MG
    • Bengbu, Anhui, China
    • +9 more
    Nov 15, 2020

    Chronic Hepatitis b, Hepatitis B Reactivation Trial in Taiwan (Vemlidy)

    Recruiting
    • Chronic Hepatitis b
    • Hepatitis B Reactivation
    • Chiayi City, Taiwan
    • +6 more
    Aug 4, 2021

    Chronic HBV Infection Trial in China (Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs), HH-003 and NrtIs, HH-003,

    Recruiting
    • Chronic HBV Infection
    • Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)
    • +2 more
    • Beijing, Beijing, China
    • +7 more
    Feb 23, 2023

    Thymidine Kinase 2 Deficiency Trial (MT1621)

    Withdrawn
    • Thymidine Kinase 2 Deficiency
    • (no location specified)
    Aug 16, 2022

    Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil)

    Terminated
    • Hepatitis B, Chronic
    • Hillsborough, New Jersey
    • +11 more
    Dec 28, 2022

    Hepatitis B Trial in Worldwide (GSK3228836, Placebo, Nucleos(t)ide therapy)

    Completed
    • Hepatitis B
    • Los Angeles, California
    • +120 more
    Jul 1, 2022

    Hepatitis B Trial in Worldwide (GSK3228836)

    Recruiting
    • Hepatitis B
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
    • +40 more
    Jul 28, 2022

    Liver Fibrosis Trial (PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate, Tenofovir Disoproxil Fumarate)

    Not yet recruiting
    • Liver Fibrosis
    • PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate
    • Tenofovir Disoproxil Fumarate
    • (no location specified)
    Nov 17, 2020

    Improvement of Hard Endpoint in Chronic Hepatitis B Patients

    Active, not recruiting
    • Chronic Hepatitis B
    • Nucleos(t)ide Analogues
    • Beijing, Beijing, China
    • +3 more
    Apr 9, 2021

    Hepatitis B, Chronic Trial in Worldwide (Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF))

    Withdrawn
    • Hepatitis B, Chronic
    • Entecavir (ETV)
    • +2 more
    • Kolding, Denmark
    • +29 more
    Oct 27, 2022

    Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, JNJ-64300535, ETV monohydrate)

    Active, not recruiting
    • Hepatitis B, Chronic
    • Edegem, Belgium
    • +12 more
    Jan 17, 2023